Cmo Europe Companies - Top Cmos Cdmos In Europe

Pharma Tech Outlook: Pharma Tech Magazine

Cerbios: Innovating End-to-End CDMO Services

Top 10 CMOs/CDMOs in Europe - 2022


Since March 2020, the global contract manufacturing market has grown at an exponential rate owing to the COVID-19 pandemic. Pharma companies, in particular, are struggling with the rising ubiquity of chronic diseases and constant demand for medicines, leading them to free their in-house resources for different projects and improve timeline and supply chain flexibility. The emerging stringent pharma regulations are also compelling companies to outsource the manufacturing of their products to CMOs. This has led to the mushrooming of contract manufacturing organizations (CMOs) capable of boosting the manufacturing efficiencies of pharma companies.

Therefore, to address the increasing demand for outsourcing, several new companies are entering the market with advanced manufacturing solutions. This trend is resulting in some of the major pharmaceutical companies outsourcing their production to service providers. Looking ahead, advances in clinical trials of several drugs will have a direct impact on the growth of the market over the coming years. In fact, the global pharmaceutical CMO market was valued at $120.29 billion in 2020 and is expected to reach $195.70 billion by 2026, registering a CAGR of 7.85 percent from 2021 to 2026.

At this juncture, several CMOs are entering the industry with some of the most advanced offerings. This edition of Pharma Tech Outlook has compiled a list of some of the most prominent players in the CMO market to aid the pharmaceutical companies in improving their outcomes and facilitating growth. Besides, the magazine also includes insights and advice from thought leaders on the industry trends, best practices, and recent innovations for aspiring business leaders.

We present to you Pharma Tech Outlook’s “Top 10 CMOs/CDMOs in Europe — 2022.”

    Top CMOs/CDMOs in Europe

  • Adragos Pharma offers a comprehensive range of pharmaceutical services, from formulation to analytical expertise, from pilot scale to commercial production, for sterile and non-sterile liquids, solids, and semi-solids. The firm is uniquely positioned in the market due to its relatively small size, concurrently offering agility, flexibility, and longstanding experience. All of Adragos Pharma’s operations are geared towards high levels of quality and reliability, and every site can conduct in-house stability testing according to ICH guidelines.

  • Specialises in the development and manufacturing of chemical and biological APIs alongside the supply of cGMP clinical batches,registration/validation material, and commercial manufacturingcapabilities.

  • As a fully integrated small molecule CDMO, Flamma offers a unique opportunity to accelerate small molecules to the pharmaceutical marketplace. With the ability to leverage FDA inspected cGMP Italian production facilities along with its fully-owned Chinese facilities (and now a cGMP site in the USA), Flamma provides a stable, secure supply chain for Active Pharmaceutical Ingredients (APIs), New Chemical Entities (NCEs), Registered Starting Materials (RSMs) and Key Intermediates. With the consolidation in the CDMO space, a void has been created for many biotech and pharma companies who are looking for CMC services. To this end, Flamma, which started initially as a catalog company supplying amino acids, has become a well-respected and highly regarded CDMO.

  • KBI Biopharma is an award-winning biopharmaceutical contract services organization providing fully integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. With each of their 500+ client partners, they work closely to personalize and rapidly accelerate their drug development programs. Built upon a foundation of world-class analytical capabilities, KBI delivers efficient process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs.

  • Olon is a global leader in developing and producing active pharmaceutical ingredients (APIs) for CDMO and generics. The company is in the process of building a new R&D hub, which will serve as a centre of excellence for CDMOs and generics developers across the country and the rest of Europe.

  • Birgi Mefar Group

    Birgi Mefar Group

    Birgi Mefar Group offers full service Pharmaceutical CDMO services to wide range of local and Fortune 500 Pharmaceutical companies from solution preparation, aseptic filling, packaging, cold chain management and serialization. Mefar also has full service analytical labs performing scale up batches to stability studies and technology transfer. Mefar has certifications from the Turkish Health Authority, EMA, SFDA, Russian, and total of 14 GMP certifications.

  • Celonic


    Celonic Group is a privately owned CDMO with two state-of-the-art sites located at Basel (headquarters), Switzerland and Heidelberg, Germany. Providing comprehensive GMP development and manufacturing services for New Biological Entities (NBEs) and Biosimilars, worldwide, and Cell Therapy & Gene associated services worldwide. Celonic’s services include the development of cell lines, production processes, as well as non-GMP and GMP manufacturing of biopharmaceutical drug substances and drug product. To complement their services with cell line development, Celonic uses its proprietary CHOvolution™ cell line technology and the human cell line GEX® for your easy or difficult target. Being part of the JRS Pharma family, Celonic is a strong believer in creating win-win value propositions for the clients, mitigating risks by mutually-beneficial business models. Celonic is ambitious, driven by the courage to think big and the commitment to get it done.



    HALIX is a fast growing, biopharmaceutical contract development and manufacturing organization (CDMO) focused on viral vector and recombinant protein products. We support our customers with the development & commercialization of biologics enabling the treatment & prevention of life threatening conditions such as cancer, COVID-19, influenza and other infectious diseases. Our state of the art GMP manufacturing facilities and our experienced and dedicated team of people ensures manufacturing capabilities which meet the highest quality standards, a service oriented way of working and a flexible mindset.



    A CDMO services provider that offers a portfolio of comprehensive and reliable pharmaceutical analytical and manufacturing processes that allow drug manufacturers to scale up in a highly competitive marketplace rapidly

  • Reig Jofre

    Reig Jofre

    Founded in 1929 in Barcelona, Spain, Reig Jofre is a pharmaceutical company listed on the Spanish Stock Exchange market, under the ticker RJF, dedicated to the research, development, manufacture and marketing of pharmaceutical products and food supplements. Reig Jofre has more than 1,100 employees, 4 development and production centres in Europe (2 in Toledo, 1 in Barcelona and 1 in Sweden), direct sales in 7 countries and more than 130 business partners in more than 70 countries around the world.